Published online Nov 16, 2019. doi: 10.4253/wjge.v11.i11.531
Peer-review started: March 18, 2019
First decision: May 9, 2019
Revised: September 25, 2019
Accepted: October 18, 2019
Article in press: October 18, 2019
Published online: November 16, 2019
Processing time: 242 Days and 3.5 Hours
Pancreatic cysts are increasingly being identified in asymptomatic patients. Establishing a diagnosis of pancreatic cystic lesions (PCLs) preoperatively still remains a challenge. Endoscopic ultrasound (EUS)-fine-needle aspiration (FNA) showed high specificity in diagnosing mucinous cysts and high grade atypia. However, the sensitivity is not enough high because of relatively acellular samples. Recently, EUS-through-the-needle biopsy (EUS-TTNB) using microforceps was recently used to make a definitive diagnosis of PCLs. There have been some studies showing the efficacy and safety of EUS-TTNB for PCLs.
The number of studies describing the safety and efficacy of EUS-TTNB is still small. There have been no study evaluating the feasibility of intraductal papillary mucinous neoplasm (IPMN) subtyping using EUS-TTNB specimen.
The aim of this study was to evaluate the safety and efficacy of EUS-TTNB, compare the tissue acquisition and diagnostic tissue yield of EUS-TTNB with EUS-FNA, and assess the feasibility of IPMN subtyping using EUS-TTNB specimen.
A retrospective analysis of endoscopy reporting system and medical records of patients who underwent EUS-TTNB for PCLs was conducted. The review and analysis were conducted through our endoscopy reporting system (endoPRO iQ®) and medical records.
A total of 56 patients with PCLs were included. The clinical success rate using EUS-TTNB (80.4%) was much higher than EUS-FNA (25%). Adverse events occurred only in 2 patients (3.6%) who developed mild pancreatitis that resolved with medical therapy. Subtyping of IPMN was successful in 23 of 32 cases (71.9%) using TTNB specimens.
EUS-TTNB is a safe and feasible procedure for evaluation of PCLs. The clinical success rate was higher in EUS-TTNB than in EUS-FNA. IPMN subtype was also possible in many cases.
Given recent development of genetic mutation analysis of PCLs, risk stratification using EUS-TTNB specimen might be possible in the future.